Please use this identifier to cite or link to this item:
Scopus Web of Science® Altmetric
Full metadata record
DC FieldValueLanguage
dc.contributor.authorInacio, M.-
dc.contributor.authorPratt, N.-
dc.contributor.authorRoughead, E.-
dc.contributor.authorGraves, S.-
dc.identifier.citationBMC Musculoskeletal Disorders, 2015; 16(1):385-1-385-9-
dc.description.abstractBackground: Joint arthroplasty patients have a high prevalence of co-morbidities and this impacts their surgical outcomes. There are different ways to ascertain co-morbidities and appropriate measurement is necessary. The purpose of this study was to: (1) describe the prevalence of co-morbidities in a cohort of total hip arthroplasty (THA) and knee arthroplasty (TKA) patients using two diagnoses-based measures (Charlson and Elixhauser) and one prescription-based measure (RxRisk-V); (2) compare the agreement of co-morbidities amongst the measures. Methods: A cross-sectional study of Australian veterans undergoing THAs (n = 11,848) and TKAs (n = 18,972) between 2001 and 2012 was conducted. Seventeen co-morbidities were identified using the Charlson, 30 using the Elixhauser, and 42 using the RxRisk-V measure. Agreement between co-morbidities was calculated using Kappa (κ) statistics. Results: Combining measures, 64 conditions were identified, of these 28 were only identified using the RxRisk-V, 11 using the Elixhauser, and 2 using the Charlson. The most prevalent conditions was pain treated with anti-inflammatories (58.7 % THAs, 55.9 % TKAs), pain treated with narcotics (55.0 % THAs, 50.9 % TKAs), hypertension (56.0 % THAs and TKAs), and anticoagulation disorders (53.0 % THAs, 48.6 % TKAs). Diabetes was the only condition with substantial agreement (all κ > 0.6) amongst all measures. When comparing the diagnoses based algorithms, agreement was high for overlapping conditions (all κ > 0.71). Conclusions: Different measures identified different co-morbidities, provided different estimates for the same co-morbidity, and had different levels of agreement for common co-morbidities. This highlights the importance of understanding co-morbidity measures and using them appropriately in studies and case-mix adjustments analyses.-
dc.description.statementofresponsibilityMaria C. S. Inacio, Nicole L. Pratt, Elizabeth E. Roughead and Stephen E. Graves-
dc.publisherBioMed Central-
dc.rights© 2015 Inacio et al. Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (, which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver ( applies to the data made available in this article, unless otherwise stated.-
dc.subjectCo-morbidities; total joint arthroplasty; pharmacy data; RxRisk-V; Charlson; Elixhauser-
dc.titleComparing co-morbidities in total joint arthroplasty patients using the RxRisk-V, Elixhauser, and Charlson Measures: a cross-sectional evaluation-
dc.typeJournal article-
dc.identifier.orcidPratt, N. [0000-0001-8730-8910]-
dc.identifier.orcidGraves, S. [0000-0002-1629-319X]-
Appears in Collections:Aurora harvest 4
Medicine publications

Files in This Item:
File Description SizeFormat 
hdl_118806.pdfPublished version386.37 kBAdobe PDFView/Open

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.